Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTXNASDAQ:BCELNASDAQ:KTTANASDAQ:VCNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.09-8.4%$1.29$0.85▼$4.40$38.29M0.2531,556 shs44,670 shsBCELAtreca$0.09$0.09$0.05▼$1.20$3.57M1.034.61 million shsN/AKTTAPasithea Therapeutics$0.77-1.4%$1.14$0.71▼$7.50$5.77M0.332.07 million shs345,243 shsVCNXVaccinex$0.71-13.4%$0.81$0.25▼$8.90$1.85M1.155,895 shs3,555 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-8.40%-12.80%-14.17%-16.15%-65.51%BCELAtreca0.00%0.00%0.00%0.00%0.00%KTTAPasithea Therapeutics-1.42%-13.91%-18.95%-28.92%-85.27%VCNXVaccinex-13.41%-21.11%-31.73%+10.94%-89.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABCELAtrecaN/AN/AN/AN/AN/AN/AN/AN/AKTTAPasithea Therapeutics1.5668 of 5 stars0.05.00.00.02.61.70.6VCNXVaccinexN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 0.00N/AN/AN/ABCELAtreca 0.00N/AN/AN/AKTTAPasithea Therapeutics 0.00N/AN/AN/AVCNXVaccinex 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/ABCELAtrecaN/AN/AN/AN/A$2.01 per shareN/AKTTAPasithea TherapeuticsN/AN/AN/AN/A$22.46 per shareN/AVCNXVaccinex$388K4.76N/AN/A($2.59) per share-0.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/A8/18/2025 (Estimated)BCELAtreca-$97.16M-$2.50N/AN/AN/AN/A-157.90%-71.39%N/AKTTAPasithea Therapeutics-$15.96M-$10.60N/A∞N/AN/A-81.57%-74.31%8/11/2025 (Estimated)VCNXVaccinex-$20.25M-$48.27N/A∞N/AN/AN/A-383.58%8/12/2025 (Estimated)Latest BCEL, AKTX, VCNX, and KTTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025KTTAPasithea TherapeuticsN/A-$1.61N/A-$1.61N/AN/A3/24/2025Q4 2024KTTAPasithea TherapeuticsN/A-$2.41N/A-$2.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ABCELAtrecaN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.290.29BCELAtrecaN/A1.581.58KTTAPasithea TherapeuticsN/A14.8214.82VCNXVaccinexN/A0.770.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%BCELAtreca37.47%KTTAPasithea Therapeutics23.92%VCNXVaccinex50.11%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.90%BCELAtreca11.30%KTTAPasithea Therapeutics16.30%VCNXVaccinex51.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.18 million16.25 millionNot OptionableBCELAtreca13039.62 million35.15 millionOptionableKTTAPasithea Therapeutics37.44 million1.06 millionNot OptionableVCNXVaccinex402.60 million1.26 millionNo DataBCEL, AKTX, VCNX, and KTTA HeadlinesRecent News About These CompaniesVaccinex presents promising cancer treatment data at ASCOMay 29, 2025 | uk.investing.comVaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025May 29, 2025 | nasdaq.comVaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual MeetingMay 27, 2025 | globenewswire.comAbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug TargetsMay 13, 2025 | finanznachrichten.deAbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug TargetsMay 13, 2025 | finance.yahoo.comVaccinex to report new clinical data on pepinemab in enhancing immunotherapyApril 22, 2025 | markets.businessinsider.comVaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025April 21, 2025 | quiverquant.comVaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)April 21, 2025 | globenewswire.comVaccinex director resigns, no disagreement citedMarch 21, 2025 | investing.comVaccinex plans Nasdaq exit as Alzheimer market pressure growsMarch 11, 2025 | finance.yahoo.comVaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock MarketMarch 8, 2025 | finanznachrichten.deVaccinex to delist common stock from NasdaqMarch 7, 2025 | markets.businessinsider.comVaccinex Plans to Delist its Common Stock from The Nasdaq Stock MarketMarch 7, 2025 | globenewswire.comPepinemab by Vaccinex for Alzheimer’s Disease: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comVaccinex receives delisting notification from NasdaqDecember 17, 2024 | markets.businessinsider.comVaccinex Announces Receipt of Delisting Notification from NasdaqDecember 17, 2024 | markets.businessinsider.comVaccinex Shares Tumble 63% On Nasdaq DelistingDecember 17, 2024 | marketwatch.comVaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%December 17, 2024 | finance.yahoo.comVaccinex Faces Nasdaq Delisting: What's Going On With The Stock?December 17, 2024 | benzinga.comVaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing StandardsDecember 17, 2024 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCEL, AKTX, VCNX, and KTTA Company DescriptionsAkari Therapeutics NASDAQ:AKTX$1.09 -0.10 (-8.40%) Closing price 06/16/2025 03:59 PM EasternExtended Trading$1.10 +0.01 (+0.92%) As of 06/16/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Atreca NASDAQ:BCELAtreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.Pasithea Therapeutics NASDAQ:KTTA$0.77 -0.01 (-1.42%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$0.77 0.00 (-0.49%) As of 06/16/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Vaccinex NASDAQ:VCNX$0.71 -0.11 (-13.41%) As of 06/16/2025 11:21 AM EasternVaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
